MedTrace Logo

Rituximab+Standard CHOP vs Rituximab+Bi-weekly CHOP for Untreated Stage III/IV Low-grade B-cell Lymphoma (JCOG0203)

NCT00147121 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2016-09-22

No results posted yet for this study

Summary

To establish standard therapy for patients with advanced-stage low grade B-cell lymphoma

Conditions

  • Lymphoma, B-Cell

Interventions

DRUG

Rituximab + Standard CHOP

Rituximab + Standard CHOP

DRUG

Rituximab + Bi-weekly CHOP

Rituximab + Bi-weekly CHOP

Sponsors & Collaborators

  • Ministry of Health, Labour and Welfare, Japan

    collaborator OTHER_GOV

  • Haruhiko Fukuda

    lead OTHER

Principal Investigators

  • Kensei Tobinai, M.D.,Ph.D. · National Cancer Center Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
69 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-09-30
Primary Completion
2010-02-28
Completion
2010-02-28

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00147121 on ClinicalTrials.gov